Our portfolio-based model enables us to advance programs efficiently and de-risk investment.  A centralized team works alongside asset-level “General Managers” & subject matter experts, enabling an acute focus on developing each therapy, while prioritizing experiments and iteratively & rigorously evaluating each program to de-risk early.  This efficiency further leverages our clinical, market access and commercialization expertise across the portfolio, allowing us to scale a robust and potentially transformative pipeline.  By ensuring each asset has a dedicated team, we are able to focus on driving rapid program advancement while ensuring there are clear paths through to approval, reimbursement, adoption and patient access.